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ABSTRACT
Objectives Serum neurofilament light chain (NfL) has 
been proposed as prognostic markers in neurogenerative 
disease. A cross- sectional study in cerebral small vessel 
disease (SVD) reported an association with cognition 
and disability. If NfL is to be used to predict outcome, 
studies are required to demonstrate baseline NfL 
predicts future dementia risk. Furthermore, if it is to be 
used as a surrogate marker in clinical trials, change in 
NfL over time periods typical of a clinical trial must be 
linked to clinical progression. In a longitudinal study of 
patients with lacunar stroke and confluent white matter 
hyperintensities, we determined whether both baseline, 
and change, in NfL levels were linked to changes in MRI 
markers, cognitive decline and dementia risk.
Methods Patients underwent MRI, cognitive testing 
and blood taking at baseline and annually for 3 years. 
Clinical and cognitive follow- up continued for 5 years.
Results NfL data were available for 113 subjects for 
baseline analysis, and 90 patients for the longitudinal 
analysis. Baseline NfL predicted cognitive decline (global 
cognition β=−0.335, SE=0.094, p=0.001) and risk of 
converting to dementia (HR=1.676 (95% CI 1.183 to 
2.373), p=0.004). In contrast to imaging, there was no 
change in NfL values over the follow- up period.
Conclusions Baseline NfL predicts changes in MRI 
markers, cognitive decline and dementia rate over a 5 
years follow- up period in SVD, suggesting NfL may be a 
useful prognostic marker. However, change in NfL values 
was not detected, and therefore NfL may not be a useful 
surrogate marker in clinical trials in SVD.
INTRODUCTION
Cerebral small vessel disease (SVD) is a highly 
prevalent condition, which causes lacunar stroke, 
vascular cognitive impairment and vascular 
dementia.1 Few treatments have been shown to 
delay disease progression. One challenge in testing 
therapies is that, while on a population basis MRI 
features of SVD predict dementia, predicting which 
individual patients will progress is difficult.2 This 
has led to calls for better markers to predict progres-
sion to dementia. Furthermore such markers may 
be useful as surrogate markers in disease studies. 
Due to the variable progression rate large sample 
sizes are required for clinical trials, and markers, 
which are sensitive to change would allow treat-
ments to be tested in smaller phase 2 trials.3 MRI 
markers including white matter hyperintensities 
(WMH) and diffusion tensor imaging (DTI) have 
been suggested as surrogate markers.3
Neurofilament light chain (NfL) is a blood marker 
sensitive to neuroaxonal damage and increased 
levels occur in neurodegenerative diseases.4 5 In a 
cross- sectional study in SVD, NfL levels were asso-
ciated with cognition and disability.6 However, if 
NfL is to be used to predict outcome, studies are 
required to demonstrate baseline NfL predicts 
future dementia risk. Furthermore if it is to be used 
as a surrogate marker in clinical trials, a change in 
NfL level within a 2–3 years period typical of a 
clinical trial must be shown to be associated with 
clinical progression. In a longitudinal prospective 
study of patients with moderate- to- severe SVD, we 
determined whether both baseline, and change, in 




Both baseline and follow- up data were used from 
the St George’s Cognition and Neuroimaging in 
Stroke (SCANS) prospective study. A total of 121 
patients with symptomatic SVD, defined as a clin-
ical lacunar stroke syndrome with MRI evidence 
of an anatomically corresponding lacunar infarct, 
and with confluent regions of WMH graded ≥2 
on the modified Fazekas scale7 were enroled from 
three stroke services in South London (St George’s 
Hospital, King’s College Hospital and St Thomas’ 
Hospital) at least 3 months post stroke.8 Exclusion 
criteria were any stroke not caused by SVD, other 
central nervous system diseases, major psychiatric 
disorders and any cause of white matter (WM) 
disease other than SVD. Written informed consent 
was obtained from all patients participating in the 
study. The study was granted ethical approval by 
Wandsworth Research Ethic Committee.
Subjects were followed up annually for 5 years 
with six incidences of strokes being recorded (four 
lacunar strokes, two intracerebral haemorrhages). 
MRI was performed at baseline and after 1, 2 and 
3 years. Information on dementia incidence was 
acquired annually. All blood samples had been 
collected annually at the time of MRI imaging. Of 
the 121 subjects recruited, blood was available for 
113, and in 90 patients blood samples were avail-
able from at least at two time points. Due to a small 
sample size, observations coming from follow- up 
time point 4 and 5 were removed.
Serum NfL
All assays were performed at the same time in 
2019–2020. The analysis was the same for all 
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samples using the same single- molecule array instrument (Simoa 
HD-1, Quanterix, Lexington, Massachusetts, USA) in Basel. We 
used the capture monoclonal antibody (mAB) 47:3 and the bioti-
nylated detector mAB 2:1 (UmanDiagnostics, Umeå, Sweden),9 
transferred onto the Simoa platform. Bovine lyophilised NfL 
was acquired from UmanDiagnostics. The range of the calibra-
tors was between 0 and 2000 pg /mL. Intra- assay and interassay 
variabilities were below 20%. The analytical sensitivity was 
0.32 pg /mL. All samples had signals above the assay’s analytical 
sensitivity. The NfL analysis was blind to the dementia outcome 
measures.
MRI acquisition
Images were obtained using a 1.5 T General Electric Signa HDxt 
MRI system8 employing the same image acquisition protocol 
at every time point. The following scan sequences referring to 
whole head coverage were acquired:
1. Axial Fluid Attenuated Inversion Recovery (FLAIR): repeti-
tion time (TR)=9000 ms, echo to time (TE)=130 ms, inver-
sion time=2200 ms, 28 slices of 5 mm thickness without slice 
gap, field of view=240×240 mm2, matrix=256×192
2. Coronal T1- weighted spoiled gradient recalled 
echo: TR=11.5 ms, TE=5 ms, 176 slices, field of 
view=240×240 mm2, matrix=256×192, flip angle=18° 
and characterised by 1.1 mm3 isotropic voxels
3. Axial single shot spin echo planar diffusion- weighted im-
aging: TR=15 600 ms, TE=93.4 ms, 55 slices marked by 
isotropic voxels of 2.5 mm3, field of view=240×240 mm2, 
8 non- diffusion- weighted- images (b=0 smm−2). This was 
succeeded by diffusion- weighted volumes with diffusion 
gradients applied (b=1000 smm−2) in 25 non- collinear di-
rections and the negative of these.
Conventional MRI markers
Normalised brain volume (NBV) and WMH lesion volume 
were computed as previously described in detail.8 10 NBV was 
computed from native T1 images as an estimate of size of the 
brain relative to the skull size with SIENAX as part of the 
FMRIB software library. To obtain the WMH measure, warped 
T1- weighted and FLAIR images were used to create population- 
specific tissue probability maps (TPMs). TPMs were employed 
to segment native images creating tissue classes of WM, WMH, 
grey matter (GM) and cerebrospinal fluid (CSF). WMH lesion 
volume was computed by binarising the segmentations at a 
manually determined threshold. WMH was calculated by taking 
the ratio of WMH volume to the total cerebral volume, which 
is composed of the sum of GM, WM and WMH at a tissue 
probability threshold ≥0.2. Lacune count (lacune), defined as 
3–15 mm in diameter, and cerebral microbleed count (CMB), 
defined as focal spots up to 10 mm in diameter, were detected by 
an independent trained rater in line with agreed neuroimaging 
standards.11 12
DTI analysis
Two methods to assess WM ultrastructure on DTI were used:
All WM histogram analysis measure
The analysis has been described previously.8 In brief, DTI scans 
were preprocessed and eddy- corrected using FMRIB's Diffu-
sion Toolbox in FSL software. Susceptibility distortions were 
unwarped by normalising the images to the T1 images in the 
phase- encoding direction. DTIFIT was then applied to create 
mean diffusivity maps. FLAIR to T1W and T1W to b0 regis-
trations were performed and the affine transformation matrices 
were concatenated to produce a FLAIR- to- DTI transforma-
tion.13 The TPMs were registered into DTI space employing 
these transformations. A hard segmentation method was applied 
to generate maps of tissue classes. Histogram analysis was 
conducted on the MD map in all WM regions. The summary 
histogram measures were derived from normalised histograms 
with 1000 bins. The primary outcome measure was mean diffu-
sivity peak height (MDPH) in the WM, as this has previously 
been shown to be the most sensitive parameter to change in the 
SCANS study.8
Peak width of skeletonised mean diffusivity (PSMD)
The PSMD is a fully automatically computed imaging marker 
being publicly available (http:// psmd- marker. com) and has been 
fully described previously.14 The computation is divided into 
four main modules: (1) DTI sequence on MRI, (2) WM tract 
skeletonisation using tract- based statistics, (3) excluding CSF- 
prone regions employing a custom mask and (4) histogram 
values of mean diffusion on the skeleton. The PSMD measure 
refers to the difference between the 5th and 95th percentiles of 
the histogram distribution.
Cognition and dementia diagnosis
Standardised tasks sensitive in capturing the impaired cognitive 
function in SVD were carried out annually. Full descriptions 
of the tasks have been published previously.15 Cognitive index 
scores were created by grouping the standardised measures into 
subdomain scores15: global cognition score (Global), executive 
function (EF) and processing speed (PS).





  Age, mean (SD) 70.012 (9.911)
  Sex, (% male) 74 (0.66)
  NART, mean (SD) 99.301 (15.544)





  Global, mean (SD) −0.654 (0.850)
  EF, mean (SD) −0.869 (1.092)
  PS, mean (SD) −0.987 (0.910)
SVD marker
  Serum NfL (pg/mL), mean (range),
  median (IQR)
36.505 (5.7–708.9)
23.20 (16.90)
  MDPH (mm2/s), mean (SD) 0.015 (0.003)
  PSMD (mm2/s), mean (SD) 3.864e-04 (1.113e-04)
  NBV (ml), mean (SD) 1292.199 (87.946)
  WMH (% brain), mean (range)
  median (IQR)
3.507 (0.29–12.81)
3.210 (2.948)








CMB, cerebral microbleeds count; EF, executive function; Global, global cognition; 
Lacune, lacune count; MDPH, mean diffusivity normalised peak height; mRS score, 
modified rankin scale; NART, premorbid IQ; NBV, normalised brain volume; NfL, 
neurofilament light chain; PS, processing speed; PSMD, Peak Width of Skeletonised 
Mean Diffusivity; WMH, White Matter Hyperintensity Lesion Load.
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Dementia was diagnosed using the Diagnostic and Statistical 
Manual of Mental Disorders-5 (DSM-5) definition of major 
neurocognitive disorder, as previously described,16 and was 
made under one of the following criteria:
1. Dementia was diagnosed in a memory clinic or in a similar 
clinical service
2. A neurologist and a clinical neuropsychologists who were 
both blind to all imaging and risk factor information re-
viewed medical records as well as cognitive data and together 
agreed that a patient met the DSM-5 criteria.
3. Significant cognitive impairment and reduced capabilities in 
daily living indicated by a consistently reduced score of <24 
in the mini- mental state examination (MMSE) and of ≤7 on 
the instrumental activities of daily living.
Disability
Disability was assessed using the modified Rankin Scale,17 18 a 
7- point scale measuring disability during stroke.
Statistical analysis
The statistical analysis was carried out using R (version 3.6.3). 
NfL, WMH lesion load, lacune and CMB count were log 10 
transformed due to the skewness of their data distribution. One 
outlier observation at baseline was excluded as being nearly 30 
times higher than any of the patient’s follow- up NfL values. This 
patient did not show any clinical aspects that could explain such 
a high value as being 63 years old, having been diagnosed with 
diabetes and having suffered a clinical stroke 7 years ago.
Associations between NfL and DTI- MRI variables were tested 
using Spearman’s rank correlations. Relationships between NfL 
or imaging measures and cognition were tested using linear 
regression after controlling for the clinical markers age, gender 



































































































































































































































































































































































































































































































































































































































































Figure 1 Higher levels of NfL was associated with a higher SVD marker 
on imaging. Spearman’s rank correlation shows the cross- sectional 
associations between MRI markers and NfL. Blue and red quartiles 
show significant positive and negative correlations. White tiles show no 
significant association. CMB, cerebral microbleed count; Lac, lacune count; 
MDPH, mean diffusivity normalised peak height; NfL, neurofilament light 
chain; NBV, normalised brain volume; PSMD, peak width of skeletonised 
mean diffusivity; SVD, small vessel disease; WMH, white matter 
hyperintensity.
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model the association between NfL and disability was tested 
while controlling for baseline age.
The effect of time on change in cognition for Global and 
PS over the five follow- up years was estimated using a linear 
mixed model (lme4).19 Fixed effect variation was explained by 
the study’s duration, and random effect variation accounted 
for the residual inter- individual differences. The linear trajec-
tory of each patient’s intercept and slope were let to vary 
with both fixed and random effects. The average fixed effects 
slopes of time are the average annualised change rate for a 
given cognition. Using maximum likelihood estimation to fit 
the model, the missing slope for one participant was estimated 
by taking information from all other patients included in the 
model.
To determine the predictive association between baseline 
NfL or baseline DTI and cognitive decline, a linear regression 
model was employed. Baseline cognition together with the clin-
ical markers age, gender and NART were added as confounders. 
Employing a logistic regression, it was furthermore tested 
whether baseline NfL predicted an increase vs no increase in 
mRS as a binary outcome over 5 years while controlling for age 
and its baseline disability score.



















































  Median baseline value (range) Number of patients with incident findings
Lacune (count) 2 (0 to 26) 24
CMB (count) 0 (0 to 41) 32
Estimated annual rates of change are defined as the mean estimates of the fixed effects from the linear mixed effect models with their 95% CI.
Significant at p value <0.05.
CMB, cerebral microbleeds count; Global, global cognition; Lacune, lacune count; MDPH, mean diffusivity normalised peak height; NBV, normalised brain volume; NfL, 
neurofilament light chain; PS, processing speed; PSMD, peak width of skeletonised mean diffusivity; SVD, small vessel disease; WMH, white matter hyperintensity lesion load.
Table 4 Longitudinal analysis
Baseline marker prediction
Dementia conversion (n=19) Decline in Global Decline in PS
β (SE) P value
HR





















0.758 −0.215 (0.098) 0.032 0.290 −0.143 (0.116) 0.224 −0.003
Serum NfL (pg /














DTI and NfL baseline markers predicting cognitive decline and dementia conversion.
Values show standardised regression coefficients: β and SEs for predictor variables in regression models of dementia conversion and decline in cognition. Significant at p value 
<0.05.
Adj R2, adjusted explained variance; AUC, area under the curve; DTI, diffusion tensor imaging; Global, global cognition; MDPH, mean diffusivity normalised peak height; NfL, 
neurofilament light chain; PS, processing speed; PSMD, peak width of skeletonised mean diffusivity.
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A cox regression model was used to test whether the base-
line NfL or imaging marker predicted dementia conversion. The 
proportional hazards assumption was met on the basis of Schoen-
feld residuals. To assess how well the predictive models’ discrim-
inatory ability classifies patients converting to dementia and 
those with no dementia at varying threshold, ROC curves were 
computed and the area under the curve (AUC) was estimated.20 
Baseline NfL and baseline clinical, imaging, cognitive character-
istics were compared between those patients showing more and 
those with less cognitive decline by employing a Welch’s t- test 
for variables with parametric distribution and the Wilcoxon rank 
sum test for variables with a non- parametric distribution.
The effect of time on change in the imaging marker and in 
NfL over the three follow- up years was estimated using a linear 
mixed model as previously described (lme4).19 Using maximum 
likelihood estimation to fit the model, the missing DTI slope for 
two participants was estimated by taking information from all 
other patients included in the model. For the dementia analysis, 
observations after the dementia diagnosis were omitted.
To determine the predictive association between the change 
in the markers and cognitive decline or dementia conversion, 
a linear regression or a cox regression model adjusted by age, 
gender and premorbid IQ was employed. The proportional 
hazards assumption was met on the basis of Schoenfeld resid-
uals and the AUC was estimated.20 Differences in clinical char-
acteristics and estimated changes in NfL and in the imaging 
markers between patients converting to dementia and those not 
converting to dementia/ censored over 5 years were tested using 
the permutation Welch’s t- test.
Finally it was also tested whether baseline and change in NfL 
predicted change in lacunes, CMB employing a logistic regres-
sion model controlling for the imaging marker’s baseline and 
age. The AUC was computed to assess diagnostic discriminatory 
ability in correctly classifying the binary outcome measures.20 
The association between baseline and change in NfL and change 
in NBV and in WMH was tested using a linear regression model 
while controlling for the imaging marker’s intercept value 
coming from the linear mixed model and baseline age.
Data availability
Cohort data can be shared on reasonable request for scientific 
purpose by contacting the corresponding author.
RESULTS
Cross-sectional analysis
Study began in January 2008 and was completed in October 
2013 with a consecutive case series design. Recruitment started in 
December 2007 and finished in August 2010. NfL data were avail-
able for 113 subjects. Clinical characteristics, cognitive measures and 
SVD markers at baseline are shown in table 1. NfL levels had a mean 
of 36.505 pg/mL, a median of 23.20 pg/mL, an IQR of 16.90 pg/
mL and a minimum and maximum of 5.7 pg/mL and 708.9 pg /mL, 
respectively. The normal range for NfL levels using this assay has 
a mean of 34.69 (SD 13.09) pg/mL for age 60–70, and a mean of 
45.85 (SD 15.31) pg /mL above age 70 years.21
NfL levels inversely associated with global cognitive function, the 
executive function and processing speed subdomain scores (table 2). 
Serum NfL also negatively correlated with disability (table 2). Higher 
NfL levels were positively associated with lacune count, CMB 
count, WMH and with DTI measures (higher PSMD and lower 
MDPH), and negatively with NBV (figure 1). We also determined 
whether association with cognition persisted after controlling for 
DTI (MDPH) and for the clinical markers; the association remained 
significant for PS but not for Global or EF (table 2).
Longitudinal analysis
Prediction by baseline NfL
There was a significant decline in both Global and PS over the 5 years 
follow- up (table 3). Higher NfL at baseline predicted lower func-
tion in Global (β=−0.335 (SE=0.094), p=0.001) independently 
of the clinical markers and baseline cognition (table 4). Higher NfL 
Table 5 Longitudinal analysis
Change marker prediction
Dementia conversion
(n=15) Decline in Global Decline in PS
Cohort β (SE) P value HR
(95% CI)
AUC β (SE) P value Adj. R β (SE) P value Adj. R
Serum NfL (pg/mL) (log 10) 0.178
(0.301)



























Change in DTI but not in NfL predicts cognitive decline and dementia conversion.
Values show standardised regression coefficients: β and SEs for predictor variables in regression models of dementia conversion and decline in cognition.Significant at p value 
<0.05.
Adj R2, adjusted explained variance; AUC, area under the curve; DTI, diffusion tensor imaging; Global, global cognition; MDPH, mean diffusivity normalised peak height; NfL, 
neurofilament light chain; PS, processing speed; PSMD, peak width of skeletonised mean diffusivity.
Table 6 The association between baseline and change in NfL marker 
and change in MRI markers over 3 years
Change in 



































Values show standardised regression coefficients β and SEs for predictor variables 
in regression models of change in imaging marker. Significant at p<0.05.
Adj R2, adjusted explained variance; AUC, area under the curve; CMB, cerebral 
microbleeds; Lacune, lacune count; NBV, normalised brain volume; NfL, serum 
neurofilament light chain; WMH, white matter hyperintensity lesion load.
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also predicted lower function in Global (β=−0.303 (SE=0.095), 
p=0.002), when controlling DTI to the existing regression model. 
Comparing patients showing more versus less cognitive decline 
further showed that there were significant baseline differences 
between the two groups for NART, MMSE score, NfL levels, NBV, 
lacune count and DTI measures but not for age, education, WMH 
or CMB (online supplemental table 1). Baseline NfL did not predict 
increases in mRS score (β=0.407 (SE=0.864), p=0.638).
A total of 107 patients had complete baseline DTI and NfL data 
of whom 19 converted to dementia over time. Higher baseline NfL 
predicted the risk of converting to dementia while accounting for 
the clinical markers (HR=1.676 (95% CI=1.183–2.373), p=0.004, 
table 4). MRI parameters also predicted both cognitive decline 
and dementia (table 4). The AUC for prediction for dementia was 
0.775 for NfL, 0.791 for MDPH and 0.758 for PSMD. To deter-
mine whether NfL contributed additional information above that 
provided by DTI, we additionally included baseline MDPH in the 
model resulting an increase in AUC of 0.804. Baseline MRI images 
for one patient aged 70 with a high baseline NfL level, 73.4 pg/mL, 
and who converted to dementia can be found in online supplemental 
file 1 A,B.
Baseline NfL predicted changes during follow- up in the number 
of lacunes and CMB, and also NBV independent of their initial MRI 
baseline values and the patient's age (table 5). The model’s AUC was 
0.773 and 0.822 for lacunes and CMB, respectively.
Prediction by change in NfL
There was no significant overall change in NfL over the 3 years 
follow- up period (table 3). In view of this lack of change in NfL, 
there was no association with dementia conversion (n=15) or 
change in any conventional MRI measure (tables 5 and 6). The indi-
vidual NfL over time per patient together with incidences in lacune 
are found in figure 2A–C. In contrast, DTI significantly changed over 
time (both assessed by MDPH and PSMD, table 3) that predicted 
dementia conversion (table 6). Detailed information regarding serial 
change of NfL, MRI markers and cognition for patients converting 
and not converting to dementia are found in online supplemental 
Figure 2 NfL measures and incidences of new lacune over time per patient. The grey line refers to NfL levels over time in patients without dementia 
conversion. The dotted black line refers to NfL levels over time in patients with dementia conversion. The red (left), green (middle) and orange (right) dotted 
vertical lines represent an incidence of a new lacune in a patient between baseline and TP 1, TP 1 and 2, TP 2 and 3, respectively. NfL, neurofilament light 
chain; TP, time point.
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table 2). There were significant differences between the two patient 
groups for change in MDPH but not PSMD or NfL.
DISCUSSION
In this longitudinal prospective study in patients with moderate- 
to- severe SVD, NfL levels at baseline predicted both cognitive 
decline and conversion to dementia. The level of prediction 
was similar to that found for DTI, which has been previously 
suggested as the most sensitive marker to WM damage in 
SVD,3 14 and has been shown to predict future dementia risk.16 
These findings suggest that NfL may be a useful marker to 
identify patients with SVD who are at higher risk of dementia. 
Previous evidence has shown that baseline NfL predicted disease 
severity and survival in CADASIL.22
In contrast, change in NfL measured on repeat testing at yearly 
intervals did not predict cognitive decline or dementia. This was 
because no significant change in NfL levels could be detected 
during the follow- up period. Previous evidence has shown that 
serum NfL proved to be a reliable marker.23 In contrast, change 
in DTI, with sampling over the same time periods as NfL levels, 
predicted dementia risk. This implies that while NfL levels may 
provide a simple marker to predict risk, they may not be useful 
in assessing outcome in clinical trials with a duration of a few 
years, where change in the surrogate marker needs to predict 
change in a clinical marker such as conversion to dementia.
A previous cross- sectional study has shown that NfL levels 
was associated with the markers of disease burden, cognition 
and disability in SVD.6 Cross- sectional analysis of our baseline 
data confirmed the results with NfL levels associating with the 
degree of cognitive impairment, of disability and markers of 
disease burden.
We also showed that NfL at baseline predicts changes in 
imaging markers of SVD burden such as NBV, CMB and lacunes 
but not WMH in the longitudinal analysis. This evidence is partly 
in line with previous findings in a subgroup (<60 years of age) of 
the community- based stroke- free cohort showing that baseline 
but also change in NfL levels were the two main determinants 
for explaining brain atrophy.21 It is also broadly consistent with 
recent evidence in mild SVD showing baseline NfL predicts risk 
of future lacunes.24
Why there was no significant change in NfL over 3 years in 
SCANS is uncertain and may be explained by dynamic changes 
in NfL post stroke.25 26 Findings from patients with small subcor-
tical infarcts demonstrated that NfL was elevated but eventually 
returned to normal levels after 15 months.26 In SCANS blood 
sampling was unfortunately only taken annually not allowing us 
to test monthly changes in NfL levels. An alternative explanation 
for the lack of significant change is that the rate of change in NfL 
over 3 years with a sample size of 90 patients is too low in this 
chronic disease for any association to be detected.
This study has a number of strengths. Repeated sampling 
of both MRI and blood was performed and data on dementia 
conversion at 5 years was available for all subjects. MRI included 
both conventional markers and DTI, allowing the comparative 
performance of prediction by NfL levels with those of MRI 
markers to be determined. It also has limitations. NfL levels at 
more than one time point were not available on all subjects. It 
has been shown that dropouts had worse cognitive function than 
those who remained in the study, which might result in an under-
estimation of the magnitude of cognitive, MRI and NfL changes 
over time.8
This prospective cohort study demonstrates that baseline 
NfL values predict cognitive decline and dementia rate over a 
5 years follow- up duration in patients with severe SVD. NfL 
may be a useful prognostic marker in this disease. However, in 
contrast to DTI, change in NfL values was not detected over a 
3 years follow- up period with annual sampling, suggesting NfL 
is unlikely to be a useful surrogate marker in a phase 2 clinical 
trial, although further larger studies are required to confirm this 
finding.
Twitter Hugh S Markus @Camstroke
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